News and Trends 5 Jul 2022 Brii Bio takes hepatitis B treatment option Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […] July 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 U.S. biotech financing drops 46% in Q1 compared to 2021 Venture financing deal value for U.S.-headquartered biotech companies dipped by 46% in Q1 2022 compared to Q1 2021, according to analysis from GlobalData. The data and analytics company said the decrease was due to venture capital firms becoming more selective in their investments due to the current economic and geopolitical uncertainties. Mariam Shwea, business fundamentals […] July 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever On this week’s podcast, we have three conversations: with Manfred Rüdiger, CEO of Ariceum Therapeutics; Jon Hague, Unilever’s R&D VP for homecare; and Olivier Rolland, executive director at TWB. Ambrosia and Dionymer winners at 2022 TWB Start-Up Day TWB, which sets up industrial biotechnology R&D projects and designer of innovative and sustainable solutions, announces the […] July 1, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 FMC dips into pheromone crop protection with $200M BioPhero acquisition FMC Corporation, an agricultural sciences company, has announced a definitive agreement to acquire BioPhero ApS, a Danish pheromone research and production company. The acquisition adds biologically produced pheromone insect control technology to FMC’s product portfolio and R&D pipeline. BioPhero has pioneered a yeast fermentation process for manufacturing pheromones at lower costs and with fewer production […] July 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Symrise Cosmetic Ingredients partners with evoxx technologies Symrise Cosmetic Ingredients has entered into a strategic partnership with German industrial biotech company evoxx technologies. The companies aim to develop biotechnological processes for ingredients used in beauty applications. The companies said as a result, consumers will be able to purchase beauty products with effective and responsible ingredients. Symrise said consumers today consider the ethical […] July 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Acticor Biotech gets patent for cardiovascular emergency treatment product French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036. The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both […] June 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Evolved By Nature raises $120M for biotech silk technology Evolved By Nature, the company creating a library of Activated Silk molecules from natural silk protein, has closed $120M in Series C financing. The round was led by Teachers’ Venture Growth (TVG), part of the C$242 billion Ontario Teachers’ Pension Plan Board, and Senator Investment Group, with participation from existing investors including Mousse Partners, Chanel, […] June 30, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Sirana Pharma and Pfizer to work on treatment for brittle bone disease German biotech company Sirana Pharma GmbH has entered into a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease, osteogenesis imperfecta (OI). Also called brittle bone disease, the condition is currently lacking approved drugs. Sirana Pharma focuses on the development of […] June 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 ARCH Venture Partners launches $3B fund for biotech companies ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. The new fund follows the January 2021 announcement of the $1.941 billion ARCH Venture Fund XI. “All the fundamental innovations in biotechnology are accelerating, with huge promise […] June 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Watch: Antibody Analytics opens new health sciences center A new facility dedicated to the advancement of medical research and drug development opened its doors recently in Motherwell, Scotland, as part of a major expansion. Antibody Analytics, one of Scotland’s authorities on immunology, officially cut the ribbon on its new health sciences research center. The unveiling of the new Antibody Analytics Discovery Centre, funded […] June 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Time Partners closes £30M venture fund to back life sciences startups Time Partners Limited has announced the final closing of its first advised fund, Time Boost Capital I LP, a £30 million ($36.6 million) genomics venture fund to provide match funding to startups graduating from Illumina Accelerator Cambridge, UK. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications […] June 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 MRM Health starts pouchitis clinical trial MRM Health, a Belgian clinical-stage biopharmaceutical company, has received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with pouchitis. MH002 is the first consortium therapy in which key disease-driving mechanisms guide therapeutic microbial […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email